Please upgrade your browser.
Nine-year-old JaKiah Collins had a big doctor's appointment ahead of her. She was used to coming to the hospital; she'd been in and out of hospitals for years. But this appointment was a big milestone.
In the CheckMate 214 trial, Motzer et al found higher overall survival among intermediate- and poor-risk patients with previously untreated metastatic renal-cell carcinoma who received nivolumab plus ipilimumab than among those who received sunitinib
A world-first discovery by University of Otago scientists may change the way children suffering from a rare form of kidney cancer are treated.
Once in a rare while, we hear a story of someone given months or weeks to live who ends up surviving and defiantly thriving. Like the first person to run a four-minute mile, climb Mt. Everest, or walk on the moon, such individuals are living proof that the impossible is possible. Yet because their experience is so far outside the norm, these survivors have been labeled medical anomalies and set aside from the lens of research. That is, until Kelly Turner, PhD, came along. The author of Radical Remission: Surviving Cancer Against All Odds (HarperCollins, 2014), Turner has studied hundreds of spontaneous-remission cases to see what can be learned from them.
Many cases of early-stage kidney cancer can be treated with a relatively new, nonsurgical procedure used to destroy tumors, a new study by a team led by Weill Cornell Medicine and NewYork-Presbyterian suggests. The procedure, called percutaneous ablation, involves the insertion of a needle.
Immunotherapy continues to evolve as a treatment option for various cancers; however, men may see more benefit from it more than women, according to a study published in The Lancet Oncology.
Robotic-assisted procedures have now become ubiquitous in some kinds of surgeries. What once was seen as a technological marvel is commonplace in many hospitals. But studies in recent years have shown robotic surgery performs no better than traditional surgery - even though it comes at a steeper cost to the overall health-care system.
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma (RCC). One of the biggest unanswered questions in the frontline setting of metastatic RCC is the role of PD-L1. Pal says that there is more to the PD-L1 story, particularly considering the findings of the CheckMate-214 trial. There was a clear difference in clinical outcomes for patients who were PD-L1–positive versus PD-L1–negative, Pal explains. Whether that is clinically applicable is not established.
Bristol-Myers Squibb Company BMY announced that the FDA accepted its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo for the indication first-line advanced non-small cell lung cancer (NSCLC) in patients with tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb). The FDA set an action date of Feb 20, 2019.
Ipsen, a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer Science (IACS).
|Powered by NeonCRM|